CompletedPhase 2NCT01890265
Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kyntra Bio
- Principal Investigator
- Mark Wencel, M.DVia Christi Clinic, P.A., USA
- Intervention
- Pamrevlumab(drug)
- Enrollment
- 160 enrolled
- Eligibility
- 40-80 years · All sexes
- Timeline
- 2013 – 2017
Study locations (30)
- The Kirklin Clinic, Birmingham, Alabama, United States
- David Geffen School of Medicine at UCLA, Los Angeles, California, United States
- UC Davis Medical Center, Sacramento, California, United States
- National Jewish Health, Denver, Colorado, United States
- Yale University, New Haven, Connecticut, United States
- Pulmonary Disease Specialist, PA, Kissimmee, Florida, United States
- Pensacola Research Consultants, Inc., d.b.a. Avanza Medical Research Center, Pensacola, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Via Christi Clinic, P.A., Wichita, Kansas, United States
- University of Louisville, Louisville, Kentucky, United States
- University of Maryland, Baltimore, Maryland, United States
- Steward St. Elizabeth's Medical Center, Boston, Massachusetts, United States
- Henry Ford Medical Center, Detroit, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01890265 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics